ROCKVILLE, Maryland, April 17, 2018 -- For years, if not decades, some very profitable business groups and health insurance providers have tried and pursued a discrimination strategy against ESRD patients. It’s appalling.
|
|||
The real steering playbook is outlined in today’s letter spearheaded by insurers, employers and labor unions: let’s get these people off employer-provided insurance and let’s push them onto the government rolls whether that works for them or not.
Unfortunately, many times, only when people have a personal experience (family or friend) with ESRD do they realize the difficult health care decisions patients have to make. To the powerful groups that spearheaded this letter, ESRD patients are a cost that they want shifted elsewhere. To us, they are men, women, husbands, wives, mothers and fathers who deserve the dignity to have the health care that best suits their personal and family situation, even if they need charitable help to pay for it.
Our goal is to make health coverage possible for those who can least afford it when they get kidney disease. With very few exceptions, these are patients with little to no meaningful assets. Certainly not enough to afford health care without tremendous out-of-pocket costs. We help patients with any type of insurance plan they’ve chosen, public or private. It’s ironic that the same insurers who say all ESRD patients belong on Medicare are, at the same time, denying charitable premium assistance that allows Medicare patients to afford the Medigap plans that protect them from personal financial ruin.
These groups don’t understand what these patients experience. They just look at cost and say it should be someone else’s problem to bear.
Health care coverage cannot just be for healthy people. This letter should send a chill down the spine of every person with a chronic disease. Which disease will be rejected by insurers and employers for health coverage next--cancer, diabetes, obesity or asthma? Because they won’t just stop with kidney failure.
This outright discrimination against ESRD patients, who are disproportionately members of minority groups, has to stop. It’s a life and death situation, and like previous Administrations, Congresses and courts, we believe Secretary Azar will reject this cynical effort to deny health coverage to people who need it most.
NOTE: The American Kidney Fund submitted a letter to Health & Human Services Secretary Azar today correcting false assertions in the letter from the insurance industry. The full text of the letter is available at http://www.kidneyfund.org/assets/pdf/advocacy/akf-letter-to-secretary-azar.pdf .
Alice Andors American Kidney Fund 240-292-7053 [email protected]


Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
How Marco Pharma International Preserves German Homeopathic Traditions in America
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 



